Načítá se...
Outcomes of patients with CLL treated with first line idelalisib plus rituximab after cessation of treatment for toxicity
BACKGROUND: More active therapies are needed for older and unfit patients with CLL who are not eligible for chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab. The PI3Kδ inhibitor idelalisib is effective in treatment-naïve and relapsed/refractory patients with CLL as monotherapy and...
Uloženo v:
| Vydáno v: | Cancer |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5980238/ https://ncbi.nlm.nih.gov/pubmed/27182988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30069 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|